Home Health and Wealth Commissioning 11 new pharma plants only solves 30% of the access problem

Commissioning 11 new pharma plants only solves 30% of the access problem

0
16
Commissioning 11 new pharma plants only solves 30% of the access problem
Pharm. Sesan Kareem

Building 11 pharmaceutical plants is real progress, and the government deserves credit for it. But let us be honest about what manufacturing does and does not solve.

Making a medicine in Lagos instead of importing it from Mumbai fixes the supply side. It does nothing for the patient in Ikorodu or Owerri who cannot afford the full course, forgets the second refill, or never gets diagnosed in the first place. Africa importing 70 per cent of its medicines and 99 per cent of its vaccines is a security problem. Africans not taking the medicines they already have is a mortality problem, and it is the bigger one.

At HubPharm Africa, the gap we see every day is not factory output. It is the last mile: adherence, affordability, and coordination. We have moved 400,000+ medicine packs across 32 states in Nigeria and improved adherence by 42 per cent for chronic patients. None of that depended on where the drug was made.

The access equation nobody talks about

Access is not one problem. It is four stacked problems.

Availability asks whether the medicine exists in-country. Affordability asks whether the patient can pay. Accessibility asks whether the patient can physically reach it. Adherence asks whether the patient actually takes it correctly for the full course.

The 11 new plants primarily address availability. They may modestly help affordability by cutting FX exposure and import duties. They do very little for accessibility, and nothing at all for adherence.

Here is what that looks like in practice. Nigerian studies consistently place chronic disease medication adherence between 30 and 40 per cent. Fewer than one in three hypertensive patients achieve blood pressure control. Fewer than one in ten diabetics reach glycaemic targets. The medicines already exist. The system to deliver them consistently, over years, to millions of people, does not.

That is the infrastructure gap. And unlike a factory, it cannot be commissioned in a single ceremony.

 

What technology actually delivers

Technology solves the access problem in ways brick-and-mortar cannot scale to.  First, it collapses distance. A patient in Yola no longer needs a specialist pharmacy within walking distance. They need a WhatsApp thread, a delivery network, and a pharmacist on the other end. Afiya, our AI health companion, now serves over 15,000 users across 31 countries in more than 50 languages. That reach is impossible with physical infrastructure alone.

Second, it enables continuity. Chronic care is not a transaction. It is a relationship measured in years. Digital platforms are the only affordable way to maintain that relationship at population scale, with refill reminders, symptom check-ins, laboratory coordination, and prescriber loops that would otherwise require a clinical team no Nigerian system can afford to hire.

Third, it creates data. Every dispense, every missed dose, every side effect logged becomes intelligence that improves the next intervention. That is how we know our patients achieved 42 per cent adherence improvement. Without the data layer, the manufacturing story remains anecdotal.

Fourth, it unlocks financing. HMOs, employers, and international donors will only pay for outcomes they can measure. Technology is what turns pharmacy from a cost centre into an outcomes contract.

 

The missing infrastructure

If Nigeria is serious about access, the next set of commissioning ceremonies should not be for buildings. They should be for systems.

We need a national medicine adherence infrastructure that combines specialty pharmacy, coordinated care teams, and AI-enabled patient engagement. We need reimbursement frameworks that pay pharmacists for outcomes, not just for dispensing. We need interoperable digital health records that follow the patient from clinic to pharmacy to home. We need public-private partnerships where innovators like ours are treated as national assets, not competition to be regulated into irrelevance.

The good news is that this infrastructure is significantly cheaper than 11 factories, moves faster, and has a shorter path to measurable population health impact.

 

Both, not either

Local manufacturing and access infrastructure are not competing priorities. We need both. Manufacturing gives Nigeria pharmaceutical sovereignty. Access infrastructure gives Nigerians pharmaceutical outcomes. One without the other is incomplete. A country that produces its own antihypertensives but cannot get them into patients’ bloodstreams consistently has traded one form of dependency for another.

For pharmacists, this is our moment. The profession that steps up to build the last-mile infrastructure, the adherence systems, the coordinated care models, the digital patient relationships, will define the next decade of Nigerian healthcare. The profession that waits for someone else to solve it will spend the next decade counting tablets in a shop.

We should celebrate the 11 plants. And then we should get back to the harder work. Let us not declare victory at the factory gate

 

Sesan Kareem is the founder and president of HubPharm Africa, a tech-enabled specialty pharmacy and coordinated care platform. He is a 2024 Tony Elumelu Entrepreneur and a member of the Pharma West Africa Leaders Club.

LEAVE A REPLY

Please enter your comment!
Please enter your name here